孕烷X受体在乳腺癌耐药中的研究进展  

Progress in the study of the pregnane X receptor in drug resistance in breast cancer

作　　者：韩晓旭 张楠 刘帅 Han Xiaoxu;Zhang Nan;Liu Shuai(School of Graduate,Shandong First Medical University,Jinan 250117,China;Breast Centre,Central Hospital Affiliated to Shandong First Medical University,Jinan 250013,China)

机构地区：[1]山东第一医科大学研究生部,济南250117 [2]山东第一医科大学附属中心医院乳腺疾病诊疗中心,济南250013

出　　处：《国际肿瘤学杂志》2024年第9期590-594,共5页Journal of International Oncology

基　　金：山东省自然科学基金(ZR2020MH201);山东省医学会临床科研资金——齐鲁专项(YXH2022ZX02168);济南市卫生健康委员会大数据科技计划(2022-YBD-03)。

摘　　要：孕烷X受体(PXR)是细胞色素P-450表达的关键调节因子,参与氧化应激、类固醇和胆汁酸代谢、炎症反应、细胞凋亡、细胞增殖等多种生物学行为,还参与化疗药物的代谢、运输和清除。PXR激活后可通过遗传变异与表观遗传修饰、调节细胞凋亡以及参与磷酸化/去磷酸化等途径影响乳腺癌化疗药物耐药,可能是乳腺癌耐药患者潜在的治疗靶点。The pregnane X receptor(PXR)is a crucial regulator of cytochrome P-450(CYP450)expression.It is involved in oxidative stress,steroid and bile acid metabolism,inflammatory response,apoptosis,cell proliferation and other biological behaviors,and also participates in the metabolism,transport and clearance of chemotherapy drugs.After activation,PXR can affect chemotherapy drug resistance of breast cancer through genetic variation and epigenetic modification,regulation of apoptosis,and participation in phosphorylation/dephosphorylation.It may be a potential therapeutic target for patients with breast cancer resistance.

关 键 词：乳腺肿瘤 孕烷X受体 抗药性 

分 类 号：R737.9[医药卫生—肿瘤]